11月23日晚间,"两连板"贵广网络（600996.SH，股价11.57元，市值144.3亿元）公告称，公司董事长陈彧因工作变动申请辞去公司第五届董事会董事、董 事长等职务，辞职后不再担任公司任何职务。公告中，贵广网络（维权）董事会对陈彧为公司发展所作的突出贡献表示衷心感谢。 同时，贵广网络收到控股股东贵州广播影视投资有限公司的控股股东贵州广电网络（维权）传媒集团有限责任公司有关文件，经公司实控人批复同意，推 荐代青松为公司第五届董事会董事、董事长人选，并代行总经理职责。 官网截图 陈彧任董事长仅一年半 陈彧当选贵广网络董事长还要从约一年半前说起。 记者还注意到，贵广网络是近日A股市场的焦点个股之一。东方财富数据显示，其股价在11月20日—21日实现"两连板"，两个交易日累计上涨21.03%。截 至11月21日（周五）收盘，贵广网络仍有9690.07万元封单，当日全天成交12.99亿元，换手率9.34%。 MACD金叉信号形成，这些股涨势不错！ 据贵广网络公告，陈彧1981年6月出生，其早期工作单位包括中国人民银行黔西南州中心支行、贵州省经济贸易委员会、贵州省经信委、贵州省人民政府 办公厅等。此外，其还担任过 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of $150 million for the fiscal year 2023, representing a 25% growth compared to the previous year[2]. - Total revenue for 2023 was RMB 967.26 million, a decrease of 30.1% from RMB 1,386.59 million in 2022[20]. - Gross profit for 2023 was RMB 451.13 million, resulting in a gross margin of 46.64%, up from 43.50% in 2022[20]. - Profit before tax for 2023 was RMB 43.32 million, compared to RMB 83.32 million in 2022, indicating a decline of 48.0%[20]. - Net profit for 2023 was RMB 36.45 million, down from RMB 77.48 million in 2022, representing a decrease of 53.1%[20]. - The overall operating performance was RMB 143.3 million, a decrease of 40.9% compared to RMB 242.5 million in 2022, mainly due to the significant decline in COVID-19 related testing[75]. - Gross profit was RMB 451.1 million, down 25.2% year-on-year, with a gross margin of 46.6%, an increase of 3.1 percentage points[72]. - The company achieved significant growth in other income and gains, which increased by 100.5% to RMB 138.09 million[48]. User Engagement and Market Expansion - User data showed a 30% increase in active users, reaching 1.2 million by the end of 2023, indicating strong market engagement[2]. - The company announced plans for market expansion into Southeast Asia, targeting a 10% market share within the next two years[2]. - The company plans to continue expanding its medical testing services and enhancing service quality in the coming year[24]. - The company is committed to international market expansion and seizing opportunities for specialized testing services and reagents abroad[41]. - The company remains confident in the growth potential of the specialized testing industry in China, despite macroeconomic fluctuations[40]. Research and Development - Investment in research and development increased by 15%, totaling $10 million, focusing on innovative technologies and product enhancements[2]. - The company is focused on enhancing R&D efficiency and expanding its multi-specialty product series to maintain its competitive edge[41]. - In 2023, the company added 186 new R&D testing projects, including 75 related to molecular biology testing technology[42]. - The company introduced new testing projects in neurology, including genetic testing for depression and anxiety disorders, and added 29 new cooperative hospitals in this segment[61]. Product Development and Launches - The company introduced two new products in Q4 2023, which are anticipated to contribute an additional $5 million in revenue in the upcoming quarter[2]. - In 2023, the company added 22 new CE-certified products, bringing the total number of reagents to over 150, with significant growth in NGS capture products[35]. - The core product, LymphoCare, expanded to 24 provinces, achieving a year-on-year revenue growth of 140%[36]. - The company introduced PacBio third-generation sequencing technology, becoming one of the first certified service providers in the Asia-Pacific region[37]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local competitor was completed, valued at $20 million, expected to enhance the company's market position and operational capabilities[2]. - A new partnership with a leading technology firm was established, aimed at co-developing advanced solutions, expected to generate $3 million in additional revenue[2]. - The company expanded its cardiovascular specialty testing services, establishing a strategic partnership with Shimadzu Corporation in Japan[45]. Corporate Governance and Management - The company is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[151]. - The board has adopted the principles and code provisions of the corporate governance code as the basis for its governance practices[152]. - The company emphasizes integrity, excellence, collaboration, accountability, empathy, and sustainability as core values guiding its operations[149]. - The board consists of independent non-executive directors who oversee financial reporting and risk management[139]. - The company has a diverse senior management team responsible for daily operations, including a Chief Financial Officer[144]. Financial Position and Cash Flow - Total assets as of December 31, 2023, were RMB 3,669.21 million, a slight decrease from RMB 3,725.34 million in 2022[21]. - Total liabilities decreased to RMB 774.23 million in 2023 from RMB 871.62 million in 2022, a reduction of 11.2%[21]. - Cash flow from operating activities was a net outflow of RMB 14.8 million for the year ended December 31, 2023[87]. - The company reported a net increase in cash and cash equivalents of RMB 757.3 million, ending the year with RMB 1,472.8 million[87]. - Cash and cash equivalents increased by 116.5% from RMB 680.4 million as of December 31, 2022, to RMB 1,472.8 million as of December 31, 2023[91]. Employee and Training Initiatives - The company has a total of 3,125 employees as of December 31, 2023, with ongoing training and development programs in place[105]. - The company aims to promote gender diversity in senior management recruitment to develop potential female successors for the board[200]. Use of Funds and Future Plans - The total planned use of funds amounted to HKD 2,053.6 million, with HKD 1,583.4 million utilized and a remaining balance of HKD 1,264.5 million[112]. - The company plans to utilize the remaining unutilized funds by June 30, 2025, depending on market conditions and opportunities[113].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9960） (1) 截至2023年12月31日止年度的年度業績公告； (2) 建議採納第十一次經修訂及重列的組織章程大綱及組織章程細則； 及 (3) 僅首次公開發售後受限制股份單位計劃項下現有股份的使用情況 (1) 截至2023年12月31日止年度的年度業績公告 董事會欣然宣佈本集團截至2023年12月31日止年度的經審計綜合業績以及截 至2022年12月31日止年度的比較數字。本集團的經審計綜合財務報表已由審 核委員會及核數師審閱。 於本公告中，「我們」指本公司及（如文義所指）本集團。本公告所載若干金額 及百分比數字已作約整。如任何表格的總數與所列數額的總和有任何不符之 處，皆為約整所致。 1 財務摘要 截至12月31日止年度 | | 2023年 | 202 ...

Business Performance - In the first half of 2023, the company experienced steady growth in its specialized testing business, contract research organization (CRO), and scientific research services, as hospital outpatient and inpatient volumes recovered[12]. - The company anticipates higher quality development in the second half of 2023 due to positive impacts from market and channel expansion, promotion of new specialized services, and improved macro healthcare conditions[12]. - The company adopted a more aggressive market strategy in the first half of 2023, collaborating with six well-known hospitals, including Southern Medical University and Yichang Central Hospital, to capture the specialized testing market[13]. - The company actively partnered with community medical institutions for testing projects with broad grassroots market potential, such as HPV testing and cancer screenings[13]. - The company anticipates continued growth in specialized testing services, excluding COVID-19 related tests, as recovery trends are observed across various segments[37]. - The company plans to continue expanding its clinical testing services, focusing on hematology, genetic diseases, and infectious diseases, to drive future growth[159]. Financial Results - Total revenue for the six months ended June 30, 2023, was RMB 492.8 million, a decrease of 25.3% compared to RMB 659.5 million in the same period of 2022[27]. - Non-COVID-19 related testing revenue increased by 9.2% to RMB 484.8 million, while COVID-19 related testing revenue dropped by 96.3% to RMB 7.9 million[27]. - Gross profit for the first half of 2023 was RMB 243.9 million, down 18.3% year-on-year, with a gross margin increase from 45.3% to 49.5%[28]. - Net profit for the same period was RMB 43.5 million, a decline of 31.2%, with a net profit margin of 8.8%, down 0.8 percentage points from the previous year[29]. - The company reported a net profit of RMB 43.49 million, a decline of 31.2% from RMB 63.23 million in the previous year[31]. - The company reported a net loss from the sale of property, plant, and equipment amounting to RMB 110 thousand for the six months ended June 30, 2023[171]. - The group reported a net loss from the sale of property, plant, and equipment amounting to RMB 110 thousand for the six months ended June 30, 2023[171]. Revenue Breakdown - The hematology testing segment generated RMB 296.86 million, representing a 6.5% year-on-year growth, while oncology testing surged by 247.1% to RMB 25.15 million[37]. - Non-COVID-19 testing services revenue for the six months ended June 30, 2023, was RMB 841 million, a decrease of 21.1% year-over-year, with a profit margin of 17.3%, down 6.6% from the previous year[44]. - Clinical testing services revenue for the six months ended June 30, 2023, was RMB 486,207 thousand, down from RMB 654,799 thousand in 2022, representing a decline of 25.8%[167]. - Total revenue from external customers for the six months ended June 30, 2023, was RMB 492,760,000, with the hematology testing segment contributing RMB 296,858,000, representing the largest share[160]. Expenses and Costs - The cost of sales decreased by 31.0% to RMB 248.84 million, primarily due to a reduction in COVID-19 related testing services[38]. - R&D expenses increased by 17.9% to RMB 52.78 million, reflecting ongoing investment in new technologies[31]. - The company’s administrative expenses rose by 26.8% to RMB 49.25 million, indicating increased operational costs[31]. - The group’s administrative expenses for the six months ended June 30, 2023, were RMB (38,829) thousand, compared to RMB (38,829) thousand in 2022, remaining consistent[171]. - The financing costs for the six months ended June 30, 2023, were RMB 32 million, primarily related to bank borrowings[51]. Cash Flow and Assets - Cash and cash equivalents increased by 77.1% to RMB 1,204.7 million as of June 30, 2023, compared to RMB 680.4 million at the end of 2022[58]. - The company has maintained a strong cash position with cash and cash equivalents totaling RMB 1,204,663,000 as of June 30, 2023, compared to RMB 577,748,000 at the end of the previous year[151]. - The cash flow from operating activities showed a net outflow of RMB 7,630 thousand for the six months ended June 30, 2023, compared to an outflow of RMB 7,788 thousand for the same period in 2022[150]. - The company recorded a significant increase in trade receivables, with a decrease of RMB 212,416 thousand in the previous year compared to an increase of RMB 43,386 thousand in the current period[150]. Research and Development - In the first half of 2023, the company launched 63 new R&D testing projects, including 15 related to molecular biology, 17 to flow cytometry, 14 to cytogenetics, and 6 to pathology[14]. - The company introduced 9 new bioinformatics automation analysis projects based on NGS technology, significantly improving the automation and accuracy of blood cancer NGS data analysis[22]. - The group has invested in research and development, with R&D costs amounting to RMB 52,784,000 during the reporting period, reflecting its commitment to innovation[160]. Shareholder Information - The company has unexercised stock options totaling 10,911,192 shares, representing approximately 1.11% of the total issued share capital as of the report date[72]. - The total number of unexercised stock options as of the report date includes 10,911,192 shares, with 4,028,400 options granted during the reporting period[83]. - The company has a diverse shareholder base, with multiple entities holding substantial stakes, indicating potential for strategic partnerships[116]. - The shareholding structure indicates significant control by a few major shareholders, with Guo Gui-Rong and Huang Bo being the most prominent[115]. Corporate Governance - The company is committed to maintaining strict corporate governance and has adhered to the corporate governance code[123]. - The audit committee has reviewed the interim financial information for the six months ended June 30, 2023, confirming compliance with international accounting standards[127]. - The company has adopted the standard code of conduct and confirmed compliance by all directors during the reporting period[126].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9960） 截至2023年6月30日止六個月的中期業績公告 康聖環球基因技術有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本 公司及其附屬公司（統稱「本集團」）截至2023年6月30日止六個月（「報告期」）的未 經審核簡明綜合業績。 於本公告中，「我們」指本公司及（如文義所指）本集團。 摘要 主要財務數據 下表載列我們於所呈列期間的主要財務數據是連同由截至2023年6月30日止六個 月及2022年同期的變動情況（以百分比表示）。 截至6月30日止六個月 | --- | --- | --- | |------------|------------|----------| | 2023年 | 2022年 | 同比變動 | | 人民幣千元 | 人民幣 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9960） 截至2022年12月31日止年度的 年度業績公告 康聖環球基因技術有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本 公司及其附屬公司（統稱「本集團」）截至2022年12月31日止年度（「報告期」）的綜 合業績以及截至2021年12月31日止年度的比較數字。本集團綜合財務報表已由本 公司審核委員會（「審核委員會」）及其核數師安永會計師事務所（執業會計師）審 閱。 於本公告中，「我們」指本公司及（如文義所指）本集團。本公告所載若干金額及百 分比數字已作約整。如任何表格的總數與所列數額的總和有任何不符之處，皆為 約整所致。 1 財務摘要 截至12月31日止年度 | --- | --- | --- | |------------|----- ...

Financial Performance - The company reported a revenue of HKD 209 million for the first half of 2022, reflecting a significant growth compared to the previous period[1]. - Total revenue for the six months ended June 30, 2022, was RMB 659.5 million, an increase of 50.5% compared to RMB 438.2 million for the same period in 2021[54]. - Revenue from COVID-19 related testing reached RMB 215.5 million, a significant increase of 1,940.5% from RMB 10.6 million in the previous year[50]. - Gross profit for the same period was RMB 298.7 million, up 27.8% from RMB 233.8 million, with a gross margin of 45.3%[57]. - Net profit for the six months ended June 30, 2022, was RMB 63.2 million, compared to a loss of RMB 1.5 billion in the same period of 2021, marking a significant turnaround[58]. - Adjusted net profit increased by 118.3% to RMB 63.2 million from RMB 29.0 million year-on-year[58]. - Non-COVID-19 related testing revenue grew steadily, contributing RMB 444.0 million, a 3.8% increase from RMB 427.6 million in the previous year[54]. - The company reported a basic earnings per share of RMB 0.07 for the period, recovering from a loss per share of RMB 10.33 in the previous year[182]. Market Expansion and Strategy - The user base expanded by 25% year-over-year, indicating strong demand for the company's services[1]. - The company projects a revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[1]. - The company plans to enter two new international markets by the end of 2023, aiming to diversify its revenue streams[1]. - A strategic acquisition of a local competitor is expected to be finalized in Q4 2022, which will enhance market share[1]. - The company is exploring partnerships with healthcare providers to expand its service offerings and reach[1]. - The company plans to establish a North American office to promote global reagent distribution and special testing services as part of its internationalization strategy[43]. Research and Development - Investment in R&D increased by 30% to enhance the development of new technologies and products[1]. - R&D expenditure for the first half of 2022 was RMB 44.8 million, a year-on-year increase of 5.7%, with 102 new testing projects added, representing a 124.4% increase compared to the same period in 2021[21]. - The company has authorized 65 patents as of June 30, 2022, including 11 invention patents and 53 utility model patents, with 30 patent applications submitted[22]. - The company is focusing on expanding its gynecological testing market, optimizing existing product offerings, and developing comprehensive diagnostic solutions for pregnancy-related syndromes[28]. - The company is enhancing its capabilities in genetic and rare disease testing, with significant revenue growth from pediatric specialty hospitals[30]. Operational Efficiency - The gross margin improved to 45%, up from 40% in the previous year, due to operational efficiencies[1]. - The gross margin for non-COVID-19 related testing improved to 54.9%, up from 53.4% in the previous year, indicating operational efficiency[57]. - The company launched an automated reporting system for minimal residual disease (MRD) testing, reducing report issuance time from an average of 2 hours to 1.5 seconds[47]. - The "Kangsheng Testing Platform 2.0" digital platform will be initiated in the second half of 2022 to enhance digital transformation across multiple dimensions[48]. - The company is actively building a big data warehouse for laboratory production data analysis to support business management[47]. Customer Engagement - Customer retention rate increased to 90%, reflecting improved service quality and customer satisfaction[1]. - The company established partnerships with over 40 new hospitals in hematology testing services, significantly increasing collaboration with tertiary hospitals[26]. - In the first half of 2022, the company added 35 new hospital clients in neurology testing services, despite challenges posed by the COVID-19 pandemic[27]. Financial Position and Cash Flow - Cash and cash equivalents decreased by RMB 1,284.2 million for the six months ended June 30, 2022, compared to a decrease of RMB 264.7 million in the same period of 2021[105]. - The company maintained a comprehensive treasury policy to manage liquidity through internal cash flows and bank borrowings[104]. - The debt-to-asset ratio as of June 30, 2022, was 17.5%, calculated as total liabilities divided by total assets multiplied by 100%[109]. - Cash used in investing activities was RMB 1,264.2 million, primarily due to the purchase of bank time deposits and payments related to non-listed funds[106]. - The company reported a significant increase in trade payables and notes payable, which rose to RMB 225,488 thousand, up 67.2% from RMB 134,820 thousand[187]. Shareholder Information - As of June 30, 2022, the company had 3,052 employees, with most located in Hubei, Sichuan, Beijing, and Shanghai[119]. - The company repurchased a total of 4,398,500 shares at a total cost of approximately HKD 14.8 million, indicating confidence in its business outlook[161]. - The company raised approximately HKD 2,214.0 million from the global offering, with a net amount of HKD 2,053.6 million after expenses[164]. - The company allocated 35% of the proceeds (HKD 718.8 million) for expanding its existing special inspection services to cover more hospitals[165]. - The company has a significant concentration of ownership among a few major shareholders, indicating potential influence over corporate decisions[147].

Financial Performance - The company reported a revenue increase of 25% year-over-year, reaching $150 million for the fiscal year 2021[3]. - The total revenue for the year ended December 31, 2021, was RMB 930.7 million, representing a 4.4% increase from RMB 891.4 million in 2020[52]. - The adjusted net profit for the year was RMB 81.1 million, a decrease of 12% compared to RMB 92.0 million in 2020[52]. - The gross profit margin improved to 52.2% in 2021 from 51.7% in 2020[52]. - The company reported a pre-tax loss of RMB 1.45 billion, compared to a pre-tax loss of RMB 962.4 million in 2020[52]. - Total assets reached RMB 3.19 billion, up from RMB 1.58 billion in 2020, indicating strong growth[53]. - The overall operating performance for the year ended December 31, 2021, was RMB 203.5 million, a decrease of RMB 8.9 million or 4.2% year-on-year[115]. - Adjusted net profit decreased by 11.9% to RMB 81.1 million, down from RMB 92.0 million in the previous year[93]. - The annual loss increased from RMB 970.1 million for the year ended December 31, 2020, to RMB 1,454.2 million for the year ended December 31, 2021[129]. Revenue Growth and Projections - The company provided a positive outlook for 2022, projecting a revenue growth of 20% to 25%[3]. - New product launches are expected to contribute an additional $20 million in revenue in 2022[3]. - Non-COVID-19 related testing revenue showed a robust growth of 12.3% year-on-year, driven by increased demand for medical services and an expanded customer base[101]. - COVID-19 related testing revenue decreased by 47.3% to RMB 62.1 million in 2021, down from RMB 117.9 million in 2020, reflecting a saturated market[97]. Market Expansion and Strategy - Market expansion plans include entering three new regions in Asia, targeting a 15% market share by 2023[3]. - The company is considering strategic acquisitions to bolster its market position, with a budget of $50 million allocated for potential deals[3]. - The company aims to become the leading provider of specialized testing services in China, focusing on high-end specialized tests in various fields[56]. - The company is actively developing new specialized testing series and aims to expand its business overseas as COVID-19 becomes manageable[65]. Research and Development - The company is investing $10 million in R&D for new technologies aimed at enhancing service efficiency[3]. - The company has a strong R&D team of over 250 experts, maintaining a R&D expense ratio of approximately 9% over the past three years, with R&D investment reaching 90.3 million, a year-on-year increase of 20%[81]. - The company developed an AI analysis system for human chromosome karyotyping, achieving processing speeds 4-6 times faster than traditional software, reducing report turnaround time from 14 days to 5-7 days[90]. - The company introduced proprietary AI software for peripheral blood chromosome analysis, improving report detection cycles and increasing identification accuracy to over 97%[61]. Testing Services and Innovations - The company expanded its testing services significantly, adding 50 new blood line testing projects and 143 new tertiary cooperative hospitals for neurological testing, achieving positive growth across major disease types[57]. - The company reported a doubling in sales for various steroid hormone tests in genetic testing, and significant revenue growth in tumor testing services, addressing high-risk patient screening and auxiliary diagnosis[57]. - The hematology testing segment generated RMB 535.3 million in revenue, accounting for 57.5% of total revenue, with a year-on-year growth of 14.0%[97]. - The company maintained the leading market share in hematology testing, with a significant focus on genetic and rare disease testing, neurology, infectious diseases, tumor testing, and gynecological diseases[66]. Operational Efficiency - The company aims to reduce operational costs by 10% through efficiency improvements in the supply chain[3]. - The logistics team consists of over 1,000 members, achieving a sample arrival rate of 93.07% within 24 hours, and received certification for compliance with national cold chain operation standards[85]. - The company has optimized its laboratory information system (LIS) and data center to improve data flow and reduce specimen movement, enhancing risk response capabilities[63]. Corporate Governance and Management - The company has a diverse board with members having extensive experience in finance and corporate governance[192][194]. - The company emphasizes the importance of risk management and internal controls in its financial operations[189]. - The company is committed to maintaining compliance with relevant laws and regulations in its financial reporting practices[189]. - The company’s senior management team includes Dr. Huang, Mr. Tu, and Ms. Chai, who are responsible for daily operations and strategic decision-making[195].

Operational Restructuring - The company is taking measures to ensure continued operations, including restructuring efforts in Hong Kong and Qingdao, and plans to sell the Yanglin project to improve cash flow[3] - The company has held eight meetings with institutional creditors since April 2019 to discuss its financial and operational status and debt restructuring plans[6] - The company appointed a financial advisor on December 5, 2019, to assist in evaluating its financial situation and developing a debt restructuring plan for its US dollar bonds[6] - The company is actively preparing for hearings related to liquidation petitions filed by certain bondholders, with the timeline for the debt restructuring plan dependent on negotiations with creditors[9] - The company has received support from some creditors regarding its current difficulties and is working towards a consensual restructuring[6] Bankruptcy and Legal Proceedings - The company’s subsidiary, Carnival (Qingdao) Real Estate Co., Ltd., was placed under bankruptcy reorganization by the court on August 27, 2020[8] - The management team is responsible for preparing the restructuring plan to be submitted to the court, maintaining significant involvement in the process[26] - The management's remuneration will be paid based on a percentage of the liquidated asset value as determined by the court[32] Financial Performance and Credit Losses - The independent valuation of financial guarantees has been conducted to assess impairment losses, ensuring compliance with Hong Kong Financial Reporting Standards[11] - As of December 31, 2020, the total outstanding balance of the company's guarantee contracts was RMB 1,000,000,000, with a fair value of RMB 390,000,000[13] - The default probability for all borrowers listed is 100%, with varying default loss rates, the highest being 75.9% for Beijing Angzhan Technology Development Co., Ltd.[13][15] - The expected credit loss for other receivables as of December 31, 2020, was RMB 1,517,013,898, representing a loss rate of 59.8%[21] - The expected credit loss for the company's other receivables increased from RMB 177,259,295 (14.8%) in 2019 to RMB 215,374,039 (17.5%) in 2020[21] Revenue and Operational Metrics - The average room rate for the hotel segment increased from RMB 400 in 2019 to RMB 424 in 2022, while occupancy rates improved from 45% in 2019 to 78% in 2022[18] - The total revenue from the theme park segment was RMB 572 million in 2020, with a projected revenue of RMB 39 million in 2022[20] - The company anticipates the exhibition center to start operations in 2023, with a total revenue of RMB 151 million expected in 2020[20] - The discount rate applied for cash flow valuation in the hotel segment was 8.75% for both 2021 and 2022[18] Management and Control - The company retains control over Carnival Corporation despite the initiation of bankruptcy restructuring, as it holds 64% of the common equity, thus bearing the risks and rewards associated with Carnival's performance[30] - The management team of Carnival Corporation continues to fulfill its operational responsibilities during the bankruptcy restructuring process, ensuring the preparation of financial statements[26] - The financial statements for the year ending December 31, 2020, will include Carnival's performance and financial condition as of the date of the annual results announcement[33] - The management's ability to influence Carnival's returns remains intact, as there have been no changes in shareholding or board membership since the start of the bankruptcy restructuring[29] - The assets and legal rights of Carnival have remained with the company since the start of the bankruptcy restructuring, allowing it to continue operations under existing business plans[32] - The company has not lost control over Carnival due to the bankruptcy restructuring, allowing for continued consolidation in financial reporting[33] - The assessment of control is based on the ability to influence significant activities that affect returns, which remains unchanged during the restructuring[30]

Financial Performance - The company reported a significant increase in revenue, achieving a total of $XX million for the first half of 2021, representing a YY% growth compared to the same period last year[2]. - Revenue for the first half of 2021 reached RMB 438.2 million, a 2.0% increase from RMB 429.5 million in the same period of 2020[45]. - Non-COVID-19 related testing revenue was RMB 427.6 million, representing a significant 27.4% increase from RMB 335.8 million year-over-year[45]. - COVID-19 related testing revenue dropped to RMB 10.6 million, a decrease of 88.7% compared to RMB 93.7 million in the previous year[45]. - Gross profit for the first half of 2021 was RMB 233.8 million, up 9.6% from RMB 213.3 million in the same period of 2020[45]. - Gross margin improved to 53.3%, compared to 49.7% in the first half of 2020[45]. - Adjusted net profit decreased by 26.8% to RMB 29.0 million, down from RMB 39.6 million year-over-year[45]. - The net loss for the period increased from RMB 90.8 million in H1 2020 to RMB 1,499.4 million in H1 2021, reflecting the impact of the aforementioned factors[90]. - The company recorded a loss before tax of RMB 1,498,747 thousand, significantly higher than the loss of RMB 84,891 thousand in the prior period[173]. - The company reported a net loss attributable to equity holders of RMB 1,501,702 thousand, compared to RMB 92,207 thousand in the same period last year[173]. Research and Development - The company is investing in R&D for new technologies, allocating DD% of its revenue towards innovation and development initiatives[2]. - R&D spending increased by 33.3% compared to the same period in 2020, with approximately 1,200 developed testing items[15]. - 46 new R&D projects were added in the first half of 2021, including 22 original projects and 24 other types[15]. - The proprietary AI software for peripheral blood chromosome identification achieved an accuracy rate of over 97%[16]. - The company plans to submit three to five invention patents and two to four utility model patents by October 2021[15]. - The company has initiated clinical application value verification studies for cardiovascular disease biomarkers, aiming to develop comprehensive diagnostic services for early prediction and monitoring of cardiovascular diseases[32]. - The company is exploring new fields in rheumatology and immunology, with plans to develop testing projects for six diseases, including rheumatoid arthritis and gout[32]. Market Expansion and Strategy - Market expansion plans include entering EE new regions, which are anticipated to enhance market share by FF%[2]. - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the GG sector[2]. - A new marketing strategy has been implemented, aiming to increase brand awareness and customer engagement by HH%[2]. - The company aims to expand its market presence in specialized fields and explore new areas such as organ transplantation and rheumatology to support continuous sales growth[52]. - The company plans to focus on high-precision technology and clinical needs, developing key projects in various fields including immunology and genomics, and investing in automated laboratory construction[52]. Operational Efficiency - The company reported a net profit margin of II%, reflecting improved operational efficiency compared to the previous year[2]. - Cash flow from operations increased by JJ%, providing a strong liquidity position for future investments[2]. - The company established a new laboratory in Wuhan, focusing on infectious disease diagnostics, enhancing service efficiency and specialization[37]. - The company received a national standard certification for cold chain logistics, affirming its capabilities in sample transportation[36]. Employee and Governance - As of June 30, 2021, the company had a total of 2,765 employees, primarily located in Hubei, Sichuan, Beijing, and Shanghai[113]. - The company provides competitive compensation packages based on market conditions and individual performance to retain employees[113]. - The company has established stock incentive plans to attract and retain top talent, with options granted to employees and consultants[120]. - The company adopted corporate governance principles to maintain high standards of ethics, transparency, and accountability[162]. Financial Position and Cash Flow - Cash generated from operating activities was RMB 25.82 million, an increase of 22.0% from RMB 21.08 million for the same period in 2020[98]. - The net cash used in investing activities was RMB 173.15 million, primarily due to the purchase of financial products totaling RMB 383.0 million[99]. - The net cash used in financing activities was RMB 117.36 million, mainly due to the payment of special dividends of RMB 65.2 million[100]. - Cash and cash equivalents decreased by 32.4% from RMB 841.23 million as of December 31, 2020, to RMB 568.90 million as of June 30, 2021[100]. - The company recorded a significant increase in fair value losses on financial liabilities, rising from RMB 130.4 million in H1 2020 to RMB 1,507.5 million in H1 2021, mainly due to valuation increases and additional funding rounds[88]. Shareholder Information - The company completed a share split on June 22, 2021, changing the par value from $0.001 to $0.00025, resulting in a total of 2,000,000,000 shares[115]. - The global offering raised approximately HKD 2,214 million (around RMB 1,997 million) from the issuance of 226,405,000 new shares at a price of HKD 9.78 per share[115]. - The total shares held by major shareholders indicate a significant concentration of ownership, with the top shareholders holding over 70% of the total shares[142]. - The company has not yet utilized HKD 2,003.3 million of the net proceeds as of the last practicable date[158].